{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:14:28Z","timestamp":1783415668699,"version":"3.54.6"},"reference-count":13,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Cury et al. present the first randomized placebo-controlled trial of a low-dose balanced tetrahydrocannabinol\u2013cannabidiol extract targeting cognition in Alzheimer\u2019s disease (AD). The study marks a milestone in a field long dominated by anecdotes and low-certainty evidence. While it demonstrated modest cognitive improvement on the Mini-Mental State Examination, the lack of functional and behavioral outcomes raises questions about real-world benefits. Methodological limitations, including a small sample size and limited power, temper interpretation but highlight the need for larger studies. For clinicians, this trial transforms speculation into evidence-based counseling, promoting informed dialogue while cautioning against premature clinical use of unregulated cannabis products in AD care.<\/jats:p>","DOI":"10.1177\/13872877261452183","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:58:20Z","timestamp":1780131500000},"page":"618-620","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cannabinoids for Alzheimer\u2019s disease: A promising trial, although not yet ready for the prescription pad"],"prefix":"10.1177","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-333X","authenticated-orcid":false,"given":"Jonadab","family":"Dos Santos Silva","sequence":"first","affiliation":[{"name":"Yale School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"e_1_3_3_2_2","article-title":"Cannabinoids for the treatment of dementia","volume":"2","author":"Krishnan S","year":"2009","unstructured":"Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2009; (2): CD007204.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001675"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2017.15.4.301"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/07317115.2020.1742832"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871527319666200708130745"},{"key":"e_1_3_3_7_2","article-title":"Cannabinoids for the treatment of dementia","volume":"9","author":"Bosnjak Kuharic D","year":"2021","unstructured":"Bosnjak Kuharic D, Markovic D, Brkovic T, et al. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2021; 9: CD012820.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-022-00119-y"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1053680"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.957665"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251389608"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.41"},{"key":"e_1_3_3_13_2","volume-title":"Early Alzheimer\u2019s disease: developing drugs for treatment. Guidance for industry","author":"U.S. Food and Drug Administration","year":"2024","unstructured":"U.S. Food and Drug Administration. Early Alzheimer\u2019s disease: developing drugs for treatment. Guidance for industry. Silver Spring (MD): FDA; 2024. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/early-alzheimers-disease-developing-drugs-treatment. Accessed March 12, 2024."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01185-z"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261452183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877261452183","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261452183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:26:11Z","timestamp":1783412771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877261452183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/13872877261452183"],"URL":"https:\/\/doi.org\/10.1177\/13872877261452183","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]}}}